BioCatalystWatch
FDMTWorkspace / FDMT / OverviewCompany library
4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. (FDMT)

Website

Price
Market cap
Next catalystExpected Q2 20274D-150 — wet AMD: PRISM and 4FRONT · Phase 3 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

4D-150

VEGF-A × VEGF-B × PlGF × VEGF-C

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

4D-150

VEGF-A × VEGF-B × PlGF × VEGF-C

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

4D-150

VEGF-A × VEGF-B × PlGF × VEGF-C

PreINDP1P2P3FilingApproved
4D-150

VEGF-A × VEGF-B × PlGF × VEGF-C

PreINDP1P2P3FilingApproved

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

FDMT PR & News

PR & News

FDMT SEC archive